F
Fermelanta
Biomanufacturing of plant-based ingredients via synthetic biology
About Fermelanta
Fermelanta is a high-growth Japanese Deep Tech company transforming the chemical and pharmaceutical industries through synthetic biology. Founded in 2022 as a spin-off from Ishikawa Prefectural University, the firm leverages over 15 years of academic excellence to engineer microbial "cell factories." Led by CEO Shogo Fukizaki, Fermelanta replaces inefficient plant extraction with a high-precision fermentation process, capable of producing rare metabolites like opium alkaloids and cannabinoids using only simple feedstocks like sugar. Backed by a significant ¥2 billion Series A in late 2025, the company is currently scaling its operations with a focus on building sustainable, localized supply chains for the pharmaceutical and cosmetics sectors. By integrating AI-driven optimization (collaborating with Hitachi), Fermelanta has achieved world-class yields in biosynthetic pathways, positioning itself as a central player in NIF Security of Critical Technologies and the Green Transition. Recognized by Forbes Japan as a top startup to watch in 2026, Fermelanta represents the pinnacle of Japan's modern "Biomanufacturing" sovereignty.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- Japan
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 80.2/100
- Sector
- Chemicals, Pharmacy, Biotechnology, Bioreactors, Synthetic Biology, Plant-Based, Sustainable Development Goals, Climate Tech, NIF defense security and resilience, biomanufacturing, NIF Crisis preparedness, precision fermentation
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Fermelanta.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Aug 2025 | $0 | — | Government of Japan | ↗ |
| SERIES A✓Equity / VC | Aug 2025 | $15M | $62M | Angel Bridge · Beyond Next Ventures · Universal Materials Incubator | ↗ |
Growth signals
Latest recorded traffic for Fermelanta is 1.4K monthly website visits, down 62.2% over the last three months. Fermelanta's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Plug and Play
Beyond Next Ventures
Angel Bridge
Government of Japan
Series A1 investor entered at this stage
Universal Materials Incubator
Other known investors1 additional known investor
HED
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Fermelanta on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Fermelanta’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.